1050. Phase 3 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by 23valent Pneumococcal Polysaccharide Vaccine 6 Months Later in At-risk Adults Aged 18–49 Years (PNEU-DAY): A Subgroup Analysis by Baseline Risk Factors

BACKGROUND: Risk factors (RFs) for pneumococcal disease (PD) in immunocompetent individuals include comorbidities, behavioral habits, or living in a community with increased risk of PD transmission. RF stacking of comorbidities is associated with a higher incidence of PD, approaching that of immunoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammitt, Laura, Quinn, Dean, Janczewska, Ewa, Pasquel, Francisco J, Tytus, Richard, Rajender Reddy, K, Abarca, Katia, Khaertynova, Ilsiyar M, Dagan, Ron, Dawson, Rachel, McCauley, Jennifer, Cheon, Kyeongmi, Pedley, Alison, Sterling, Tina, Tamms, Gretchen, Musey, Luwy, Buchwald, Ulrike K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644033/
http://dx.doi.org/10.1093/ofid/ofab466.1244

Ejemplares similares

Ejemplares similares